Cargando…

Haploidentical hematopoietic stem cell transplantation may improve long-term survival for children with high-risk T-cell acute lymphoblastic leukemia in first complete remission

BACKGROUND: The role of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in children with high-risk (HR) T-cell acute lymphoblastic leukemia (T-ALL) in first complete remission (CR1) is still under evaluation. Moreover, relapse is the main factor affecting survival. This study aimed to...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yongzhan, Bai, Lu, Cheng, Yifei, Lu, Aidong, Wang, Yu, Wu, Jun, Zhang, Xiaohui, Zuo, Yingxi, Xu, Lanping, Jia, Yueping, Huang, Xiaojun, Zhang, Leping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9276285/
https://www.ncbi.nlm.nih.gov/pubmed/35730372
http://dx.doi.org/10.1097/CM9.0000000000001999
_version_ 1784745687387209728
author Zhang, Yongzhan
Bai, Lu
Cheng, Yifei
Lu, Aidong
Wang, Yu
Wu, Jun
Zhang, Xiaohui
Zuo, Yingxi
Xu, Lanping
Jia, Yueping
Huang, Xiaojun
Zhang, Leping
author_facet Zhang, Yongzhan
Bai, Lu
Cheng, Yifei
Lu, Aidong
Wang, Yu
Wu, Jun
Zhang, Xiaohui
Zuo, Yingxi
Xu, Lanping
Jia, Yueping
Huang, Xiaojun
Zhang, Leping
author_sort Zhang, Yongzhan
collection PubMed
description BACKGROUND: The role of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in children with high-risk (HR) T-cell acute lymphoblastic leukemia (T-ALL) in first complete remission (CR1) is still under evaluation. Moreover, relapse is the main factor affecting survival. This study aimed to explore the effect of allo-HSCT (especially haploidentical HSCT [haplo-HSCT]) on improving survival and reducing relapse for HR childhood T-ALL in CR1 and the prognostic factors of childhood T-ALL in order to identify who could benefit from HSCT. METHODS: A total of 74 newly diagnosed pediatric T-ALL patients between January 1, 2012 and June 30, 2018 were enrolled in this retrospective study. Patients were stratified into the low-risk chemotherapy cohort (n = 16), HR chemotherapy cohort (n = 31), and HR transplant cohort (n = 27). Characteristics, survival outcomes, and prognostic factors of all patients were then analyzed. RESULTS: Patient prognosis in the HR chemotherapy cohort was significantly worse than that in the low-risk chemotherapy cohort (5year overall survival [OS]: 58.5% vs. 100%, P = 0.003; 5-year event-free survival [EFS]: 54.1% vs. 83.4%, P = 0.010; 5-year cumulative incidence of relapse [CIR]: 45.2% vs. 6.3%, P = 0.011). In HR patients, allo-HSCT improved the 5-year EFS and CIR compared to that of chemotherapy (5-year EFS: 80.1% vs. 54.1%, P = 0.041; 5-year CIR: 11.6% vs. 45.2%, P = 0.006). The 5-year OS was higher in the HR transplant cohort than that in the HR chemotherapy cohort (81.0% vs. 58.5%, P = 0.084). Minimal residual disease re-emergence was an independent risk factor for 5-year OS, EFS, and CIR; age ≥10 years was an independent risk factor for OS and EFS; and high white blood cell count was an independent risk factor for EFS and CIR. CONCLUSION: Allo-HSCT, especially haplo-HSCT, could effectively reduce relapse of children with HR T-ALL in CR1.
format Online
Article
Text
id pubmed-9276285
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-92762852022-07-13 Haploidentical hematopoietic stem cell transplantation may improve long-term survival for children with high-risk T-cell acute lymphoblastic leukemia in first complete remission Zhang, Yongzhan Bai, Lu Cheng, Yifei Lu, Aidong Wang, Yu Wu, Jun Zhang, Xiaohui Zuo, Yingxi Xu, Lanping Jia, Yueping Huang, Xiaojun Zhang, Leping Chin Med J (Engl) Original Articles BACKGROUND: The role of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in children with high-risk (HR) T-cell acute lymphoblastic leukemia (T-ALL) in first complete remission (CR1) is still under evaluation. Moreover, relapse is the main factor affecting survival. This study aimed to explore the effect of allo-HSCT (especially haploidentical HSCT [haplo-HSCT]) on improving survival and reducing relapse for HR childhood T-ALL in CR1 and the prognostic factors of childhood T-ALL in order to identify who could benefit from HSCT. METHODS: A total of 74 newly diagnosed pediatric T-ALL patients between January 1, 2012 and June 30, 2018 were enrolled in this retrospective study. Patients were stratified into the low-risk chemotherapy cohort (n = 16), HR chemotherapy cohort (n = 31), and HR transplant cohort (n = 27). Characteristics, survival outcomes, and prognostic factors of all patients were then analyzed. RESULTS: Patient prognosis in the HR chemotherapy cohort was significantly worse than that in the low-risk chemotherapy cohort (5year overall survival [OS]: 58.5% vs. 100%, P = 0.003; 5-year event-free survival [EFS]: 54.1% vs. 83.4%, P = 0.010; 5-year cumulative incidence of relapse [CIR]: 45.2% vs. 6.3%, P = 0.011). In HR patients, allo-HSCT improved the 5-year EFS and CIR compared to that of chemotherapy (5-year EFS: 80.1% vs. 54.1%, P = 0.041; 5-year CIR: 11.6% vs. 45.2%, P = 0.006). The 5-year OS was higher in the HR transplant cohort than that in the HR chemotherapy cohort (81.0% vs. 58.5%, P = 0.084). Minimal residual disease re-emergence was an independent risk factor for 5-year OS, EFS, and CIR; age ≥10 years was an independent risk factor for OS and EFS; and high white blood cell count was an independent risk factor for EFS and CIR. CONCLUSION: Allo-HSCT, especially haplo-HSCT, could effectively reduce relapse of children with HR T-ALL in CR1. Lippincott Williams & Wilkins 2022-04-20 2022-02-15 /pmc/articles/PMC9276285/ /pubmed/35730372 http://dx.doi.org/10.1097/CM9.0000000000001999 Text en Copyright © 2022 The Chinese Medical Association, produced by Wolters Kluwer, Inc. under the CC-BY-NC-ND license. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/)
spellingShingle Original Articles
Zhang, Yongzhan
Bai, Lu
Cheng, Yifei
Lu, Aidong
Wang, Yu
Wu, Jun
Zhang, Xiaohui
Zuo, Yingxi
Xu, Lanping
Jia, Yueping
Huang, Xiaojun
Zhang, Leping
Haploidentical hematopoietic stem cell transplantation may improve long-term survival for children with high-risk T-cell acute lymphoblastic leukemia in first complete remission
title Haploidentical hematopoietic stem cell transplantation may improve long-term survival for children with high-risk T-cell acute lymphoblastic leukemia in first complete remission
title_full Haploidentical hematopoietic stem cell transplantation may improve long-term survival for children with high-risk T-cell acute lymphoblastic leukemia in first complete remission
title_fullStr Haploidentical hematopoietic stem cell transplantation may improve long-term survival for children with high-risk T-cell acute lymphoblastic leukemia in first complete remission
title_full_unstemmed Haploidentical hematopoietic stem cell transplantation may improve long-term survival for children with high-risk T-cell acute lymphoblastic leukemia in first complete remission
title_short Haploidentical hematopoietic stem cell transplantation may improve long-term survival for children with high-risk T-cell acute lymphoblastic leukemia in first complete remission
title_sort haploidentical hematopoietic stem cell transplantation may improve long-term survival for children with high-risk t-cell acute lymphoblastic leukemia in first complete remission
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9276285/
https://www.ncbi.nlm.nih.gov/pubmed/35730372
http://dx.doi.org/10.1097/CM9.0000000000001999
work_keys_str_mv AT zhangyongzhan haploidenticalhematopoieticstemcelltransplantationmayimprovelongtermsurvivalforchildrenwithhighrisktcellacutelymphoblasticleukemiainfirstcompleteremission
AT bailu haploidenticalhematopoieticstemcelltransplantationmayimprovelongtermsurvivalforchildrenwithhighrisktcellacutelymphoblasticleukemiainfirstcompleteremission
AT chengyifei haploidenticalhematopoieticstemcelltransplantationmayimprovelongtermsurvivalforchildrenwithhighrisktcellacutelymphoblasticleukemiainfirstcompleteremission
AT luaidong haploidenticalhematopoieticstemcelltransplantationmayimprovelongtermsurvivalforchildrenwithhighrisktcellacutelymphoblasticleukemiainfirstcompleteremission
AT wangyu haploidenticalhematopoieticstemcelltransplantationmayimprovelongtermsurvivalforchildrenwithhighrisktcellacutelymphoblasticleukemiainfirstcompleteremission
AT wujun haploidenticalhematopoieticstemcelltransplantationmayimprovelongtermsurvivalforchildrenwithhighrisktcellacutelymphoblasticleukemiainfirstcompleteremission
AT zhangxiaohui haploidenticalhematopoieticstemcelltransplantationmayimprovelongtermsurvivalforchildrenwithhighrisktcellacutelymphoblasticleukemiainfirstcompleteremission
AT zuoyingxi haploidenticalhematopoieticstemcelltransplantationmayimprovelongtermsurvivalforchildrenwithhighrisktcellacutelymphoblasticleukemiainfirstcompleteremission
AT xulanping haploidenticalhematopoieticstemcelltransplantationmayimprovelongtermsurvivalforchildrenwithhighrisktcellacutelymphoblasticleukemiainfirstcompleteremission
AT jiayueping haploidenticalhematopoieticstemcelltransplantationmayimprovelongtermsurvivalforchildrenwithhighrisktcellacutelymphoblasticleukemiainfirstcompleteremission
AT huangxiaojun haploidenticalhematopoieticstemcelltransplantationmayimprovelongtermsurvivalforchildrenwithhighrisktcellacutelymphoblasticleukemiainfirstcompleteremission
AT zhangleping haploidenticalhematopoieticstemcelltransplantationmayimprovelongtermsurvivalforchildrenwithhighrisktcellacutelymphoblasticleukemiainfirstcompleteremission